Download Files:
Products Details
Product Description
– Olpasiran sodium is a small interfering RNA that reduces lipoprotein(a) synthesis in the liver.
Web ID
– HY-153492A
Shipping
– Room temperature
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– C490H610F11N164Na42O306P41S7
References
– [1]Sohn W, Winkle P, Neutel J, et al. Pharmacokinetics, Pharmacodynamics, and Tolerability of Olpasiran in Healthy Japanese and Non-Japanese Participants: Results from a Phase I, Single-dose, Open-label Study. Clin Ther. 2022;44(9):1237-1247. |[2]O’Donoghue ML, G López JA, Knusel B, et al. Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE). Am Heart J. 2022;251:61-69.
Molecular Weight
– 16361.91
SMILES
– [Olpasiran (sodium)]
Clinical Information
– No Development Reported
Research Area
– Cardiovascular Disease
Solubility
– 10 mM in H2O
Target
– Small Interfering RNA (siRNA)
Pathway
– Epigenetics
Product type
– Oligonucleotides
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
Related Products
1000 in stock
